At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

If that sounds like the storyline to Marvel's latest superhero tale, that's because it is. The publisher's latest custom ...

The rate for the latter half of the year brings the full-year average to 23.4% – rising to 24.3% next year and 26% in 2027 – ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

SpliceBio's lead in-house pipeline project is in Stargardt disease, an IRD with no approved therapies that is caused by ...

Makary and Prasad also repeat various themes repeatedly visited by Kennedy on his Make America Healthy Again (MAHA) soapbox, ...

Adaptive trials allow for modifications to be made during the trial without requiring additional approvals. According to the ...

Asked where AI is having the biggest impact in digital engagement, around half (49%) of respondents said it was in data ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

NewAmsterdam Pharma has said that an oral drug it is developing to lower cholesterol has shown preliminary efficacy as a ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...